

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

LIFESCAN, INC., SENSEONICS HOLDINGS, INC., and
ASCENSIA DIABETES CARE HOLDINGS AG,

Petitioners,

v.

CELLSPIN SOFT, INC.,

Patent Owner

IPR2025-00102 (Patent 11,234,121 B2)

JOINT MOTION TO TERMINATE PROCEEDING

Pursuant to 35 U.S.C. § 317(a) and 37 C.F.R. § 42.74, Petitioners LifeScan, Inc., Senseonics Holdings, Inc., and Ascensia Diabetes Care Holdings AG, together with Patent Owner Cellspin Soft, Inc. (collectively, the “Parties”), through their respective counsel of record, jointly request termination of these above-identified proceedings in view of the Parties’ resolution of their dispute relating to the Challenged Patents (U.S. Patent Nos. 11,234,121; 9,900,766; and 8,904,030). The Board authorized the filing of this Joint Motion to Terminate during a teleconference with the Parties on June 25, 2026.

Termination with respect to Petitioners and Patent Owner is appropriate in the instant proceeding because the dispute between the parties has been resolved. The Parties have reached a confidential settlement of their disputes with respect to the Challenged Patents, which includes agreements to terminate this and all related proceedings. The confidential settlement agreements between Petitioners and Patent Owner are in writing, and a true and correct copy of the settlement agreements are filed concurrently with this motion as Exhibits 1037 and 1038 in each respective case (which is submitted as “Parties and Board Only”), pursuant to 35 U.S.C. § 317(b), along with a separate Joint Request to Treat as Confidential and Keep Separate Pursuant to 35 U.S.C. § 317(b). The Parties certify that there are no other collateral agreements or understandings, oral or written, between the Parties made in connection with, or in contemplation of, the termination of this proceeding. The

Parties request that the settlement agreements be treated as business confidential information, be kept separate from the files of the involved patent, and be made available only pursuant to 35 U.S.C. § 317 and 37 C.F.R. § 42.74(c).

Pursuant to 37 C.F.R. §§ 42.5 and 42.72, the Board may terminate a trial without rendering a final written decision, where appropriate, including pursuant to a joint request under 35 U.S.C. §§ 317(a). *See Winplus N. Am., Inc. v. Pilot, Inc.*, IPR2018-00488, Paper 12 (PTAB Oct. 24, 2018). “There are strong public policy reasons to favor settlement between the parties to a proceeding... The Board expects that a proceeding will terminate after the filing of a settlement agreement, unless the Board has already decided the merits of the proceeding.” Because the Board has not already decided the merits in these actions, termination is appropriate under 34 C.F.R. § 42.72. Moreover, the parallel litigations will be dismissed pursuant to the Parties’ settlement agreement.

Therefore, for the foregoing reasons, Petitioners and Patent Owner jointly request termination of this proceeding.

//

Date: June 25, 2026

Respectfully submitted,

By: /Charles M. McMahon/

Charles M. McMahon

Reg. No. 44,926

Counsel for Petitioner LifeScan, Inc.

By: /Joseph A. Hynds/

Joseph A. Hynds

Reg. No. 34,627

Counsel for Petitioners Senseonics
Holdings, Inc. and Ascensia Diabetes
Care Holdings AG

By: /M. Scott Fuller/

M. Scott Fuller (Lead Counsel)

Reg. No. 54,716

Counsel for Patent Owner

CERTIFICATION OF SERVICE

Pursuant to 37 C.F.R. §§ 42.6(e) and 42.105(b), the undersigned certifies that on June 25, 2026, a copy of the foregoing document was served by electronic mail on the following:

sfuller@ghiplaw.com
rvazquez@sinergialaw.com
litigation@ghiplaw.com

Dated: June 25, 2026

By: /Charles M. McMahon/
Charles M. McMahon
Reg. No. 44,926